| NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | NOT_YET_RECRUITING | PHASE1, PHASE2 | 2025-10-15 | 2032-06-17 | 2030-06-17 |
| NCT07117487 | A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age | RECRUITING | PHASE3 | 2025-08-05 | 2026-04-15 | 2026-04-15 |
| NCT07089706 | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations | ACTIVE_NOT_RECRUITING | PHASE4 | 2025-07-21 | 2025-09-11 | 2025-09-11 |
| NCT06735248 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years | RECRUITING | PHASE2 | 2025-04-16 | 2029-01-08 | 2029-01-08 |
| NCT06880549 | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | RECRUITING | PHASE1 | 2025-03-25 | 2029-01-10 | 2029-01-10 |
| NCT06864143 | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age | RECRUITING | PHASE2 | 2025-03-07 | 2025-10-06 | 2025-10-06 |
| NCT06694389 | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-11-18 | 2025-12-10 | 2025-12-10 |
| NCT06655870 | A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants | RECRUITING | PHASE1 | 2024-10-31 | 2025-12-20 | 2025-12-20 |
| NCT06634797 | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age | COMPLETED | PHASE4 | 2024-10-08 | 2025-01-20 | 2025-01-20 |
| NCT06592794 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-09-24 | 2027-05-31 | 2027-05-31 |
| NCT06602024 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age | COMPLETED | PHASE3 | 2024-09-16 | 2025-08-21 | 2025-08-21 |
| NCT06585241 | A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Adults to Prevent COVID-19 | ACTIVE_NOT_RECRUITING | PHASE4 | 2024-09-09 | 2025-10-29 | 2025-10-29 |
| NCT06508320 | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-07-15 | 2025-09-17 | 2025-09-17 |
| NCT06354998 | A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults | COMPLETED | PHASE3 | 2024-04-08 | 2024-05-10 | 2024-05-10 |
| NCT06147856 | A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria | WITHDRAWN | PHASE1, PHASE2 | 2024-03-29 | 2027-08-05 | 2026-08-10 |
| NCT06243770 | Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants | COMPLETED | PHASE1 | 2024-02-16 | 2025-06-12 | 2025-06-12 |
| NCT06133010 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients | WITHDRAWN | PHASE2 | 2024-02-08 | 2027-12-14 | 2027-02-14 |
| NCT06143046 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-11-15 | 2026-02-18 | 2026-02-18 |
| NCT06097299 | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | COMPLETED | PHASE2 | 2023-10-24 | 2025-06-27 | 2025-06-27 |
| NCT06097273 | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age | COMPLETED | PHASE3 | 2023-10-19 | 2024-05-28 | 2024-05-28 |
| NCT06067230 | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-10-06 | 2026-07-30 | 2026-07-30 |
| NCT06060457 | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age | COMPLETED | PHASE3 | 2023-09-25 | 2024-06-07 | 2024-06-07 |
| NCT06033261 | A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | COMPLETED | PHASE1, PHASE2 | 2023-09-06 | 2025-04-25 | 2025-04-25 |
| NCT05992935 | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-08-25 | 2026-11-20 | 2026-04-14 |
| NCT05995275 | A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age | COMPLETED | PHASE1, PHASE2 | 2023-08-15 | 2025-07-08 | 2025-07-08 |
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | WITHDRAWN | PHASE1 | 2023-08-15 | 2026-05-27 | 2026-05-27 |
| NCT05975099 | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | COMPLETED | PHASE1, PHASE2 | 2023-07-26 | 2025-05-30 | 2025-05-30 |
| NCT05972174 | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | COMPLETED | PHASE1, PHASE2 | 2023-07-10 | 2024-07-16 | 2024-07-16 |
| NCT05868382 | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults | COMPLETED | PHASE2 | 2023-05-15 | 2023-12-19 | 2023-12-19 |
| NCT05827978 | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | COMPLETED | PHASE3 | 2023-04-17 | 2024-06-24 | 2024-06-24 |
| NCT05827926 | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | COMPLETED | PHASE1, PHASE2 | 2023-04-14 | 2024-12-03 | 2024-12-03 |
| NCT05831111 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-04-05 | 2026-10-07 | 2026-10-07 |
| NCT05683457 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. | RECRUITING | PHASE2 | 2023-04-05 | 2026-08-01 | 2026-08-01 |
| NCT05815498 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 | COMPLETED | PHASE3 | 2023-03-28 | 2025-04-12 | 2025-04-12 |
| NCT05827068 | A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults | COMPLETED | PHASE1, PHASE2 | 2023-03-27 | 2023-11-20 | 2023-11-20 |
| NCT05743881 | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-02-15 | 2026-09-30 | 2026-08-31 |
| NCT05701800 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-01-23 | 2026-06-30 | 2026-06-30 |
| NCT05659264 | A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure | COMPLETED | PHASE1 | 2022-12-05 | 2024-12-17 | 2024-12-17 |
| NCT05575492 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-11-07 | 2027-01-15 | 2027-01-15 |
| NCT05606965 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults | RECRUITING | PHASE2 | 2022-11-02 | 2025-11-11 | 2025-11-11 |
| NCT05585632 | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old | COMPLETED | PHASE1 | 2022-10-14 | 2024-02-28 | 2024-02-28 |
| NCT05584202 | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | TERMINATED | PHASE2 | 2022-09-30 | 2024-11-15 | 2024-11-15 |
| NCT05566639 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older | COMPLETED | PHASE3 | 2022-09-14 | 2024-01-05 | 2024-01-05 |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2022-09-01 | 2032-02-18 | 2032-02-18 |
| NCT05436834 | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age | RECRUITING | PHASE3 | 2022-06-21 | 2025-10-27 | 2025-10-27 |
| NCT05415462 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | COMPLETED | PHASE3 | 2022-06-06 | 2023-09-04 | 2023-09-04 |
| NCT05095727 | A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | RECRUITING | PHASE1, PHASE2 | 2022-06-01 | 2028-12-26 | 2026-05-26 |
| NCT05397223 | A Study of Modified mRNA Vaccines in Healthy Adults | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-05-24 | 2026-02-21 | 2026-02-21 |
| NCT05375838 | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old | COMPLETED | PHASE1, PHASE2 | 2022-05-13 | 2022-12-29 | 2022-12-29 |
| NCT05333289 | A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults | COMPLETED | PHASE1, PHASE2 | 2022-04-06 | 2022-11-22 | 2022-11-22 |
| NCT05330975 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age | COMPLETED | PHASE3 | 2022-04-01 | 2024-11-08 | 2024-11-08 |
| NCT05295433 | An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 | RECRUITING | PHASE1, PHASE2 | 2022-03-08 | 2034-04-02 | 2032-04-01 |
| NCT05249829 | A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 | COMPLETED | PHASE2, PHASE3 | 2022-02-16 | 2023-06-23 | 2023-06-23 |
| NCT05164094 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-12-28 | 2026-10-05 | 2026-10-05 |
| NCT05137236 | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters | COMPLETED | PHASE2 | 2021-12-06 | 2023-03-23 | 2023-03-23 |
| NCT05127434 | A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age | COMPLETED | PHASE2, PHASE3 | 2021-11-17 | 2025-07-28 | 2025-07-28 |
| NCT05130437 | A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study | RECRUITING | PHASE1, PHASE2 | 2021-11-09 | 2031-12-04 | 2029-12-04 |
| NCT05105048 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 | COMPLETED | PHASE1 | 2021-11-08 | 2023-08-10 | 2023-08-10 |
| NCT05085366 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-10-26 | 2028-04-30 | 2026-04-30 |
| NCT04899310 | A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia | RECRUITING | PHASE1, PHASE2 | 2021-08-06 | 2028-08-01 | 2026-08-01 |
| NCT04916431 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults | COMPLETED | PHASE1 | 2021-07-28 | 2022-08-02 | 2022-08-02 |
| NCT04956575 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults | COMPLETED | PHASE1, PHASE2 | 2021-07-06 | 2022-09-27 | 2022-09-27 |
| NCT04975893 | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | ENROLLING_BY_INVITATION | PHASE2 | 2021-06-18 | 2026-12-30 | 2026-12-30 |
| NCT04917861 | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | COMPLETED | PHASE2 | 2021-06-07 | 2024-07-26 | 2024-07-26 |
| NCT04927065 | A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants | COMPLETED | PHASE2, PHASE3 | 2021-05-28 | 2023-11-17 | 2023-11-17 |
| NCT04860297 | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants | COMPLETED | PHASE3 | 2021-04-16 | 2023-05-22 | 2023-05-22 |
| NCT04159103 | Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia | RECRUITING | PHASE1, PHASE2 | 2021-04-15 | 2026-01-31 | 2026-01-31 |
| NCT04796896 | A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age | COMPLETED | PHASE2, PHASE3 | 2021-03-15 | 2024-03-15 | 2024-03-15 |
| NCT04813796 | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 | COMPLETED | PHASE1 | 2021-03-11 | 2023-07-25 | 2023-07-25 |
| NCT04649151 | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 | COMPLETED | PHASE2, PHASE3 | 2020-12-09 | 2024-06-14 | 2024-06-14 |
| NCT04528719 | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | COMPLETED | PHASE1 | 2020-09-30 | 2024-07-18 | 2024-07-18 |
| NCT04470427 | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 | COMPLETED | PHASE3 | 2020-07-27 | 2022-12-29 | 2022-12-29 |
| NCT04405076 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | COMPLETED | PHASE2 | 2020-05-29 | 2021-10-28 | 2021-10-28 |
| NCT04232280 | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults | COMPLETED | PHASE2 | 2020-01-09 | 2023-01-04 | 2023-01-04 |
| NCT04144348 | Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure | COMPLETED | PHASE1 | 2019-11-04 | 2022-12-20 | 2022-12-20 |
| NCT04064905 | Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults | COMPLETED | PHASE1 | 2019-07-30 | 2021-03-22 | 2021-03-22 |
| NCT03897881 | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | RECRUITING | PHASE2 | 2019-07-18 | 2029-09-09 | 2029-09-09 |
| NCT03810690 | Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia | WITHDRAWN | PHASE1, PHASE2 | 2019-05-28 | 2020-08-18 | 2020-08-18 |
| NCT03829384 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults | COMPLETED | PHASE1 | 2019-01-22 | 2021-06-07 | 2021-06-07 |
| NCT03739931 | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies | COMPLETED | PHASE1 | 2018-11-27 | 2025-08-01 | 2025-08-01 |
| NCT03392389 | Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults | COMPLETED | PHASE1 | 2017-12-04 | 2019-07-29 | 2019-07-29 |
| NCT03382405 | Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults | COMPLETED | PHASE1 | 2017-11-13 | 2020-10-28 | 2020-10-28 |
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | TERMINATED | PHASE1, PHASE2 | 2017-08-15 | 2021-08-18 | 2021-08-18 |
| NCT03313778 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors | RECRUITING | PHASE1 | 2017-08-14 | 2027-08-01 | 2027-08-01 |
| NCT03325075 | Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants | COMPLETED | PHASE1 | 2017-07-19 | 2019-03-19 | 2019-03-19 |
| NCT03014089 | Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects | COMPLETED | PHASE1 | 2016-12-21 | 2019-07-31 | 2019-07-31 |
| NCT03345043 | Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects | COMPLETED | PHASE1 | 2016-05-11 | 2018-08-13 | 2018-08-13 |
| NCT03076385 | Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects | COMPLETED | PHASE1 | 2015-12 | 2018-10 | 2018-10 |